Health Canada updating safety labelling for benzodiazepines
- PDF / 150,978 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 8 Downloads / 222 Views
1
Health Canada updating safety labelling for benzodiazepines Health Canada is updating safety labelling for benzodiazepines and benzodiazepine-like prescription drugs (Zdrugs) used for the treatment of sleep and anxiety disorders, and some seizure disorders, and to relax muscles or relieve muscle spasms. Health Canada is working with Market Authorization Holders to update the safety labelling for these drugs with messaging about severe and potentially life-threatening risks associated with these drugs including: drug abuse and substance use disorder; severe withdrawal symptoms; drug interactions with opioid analgesics resulting in deep drowsiness, respiratory depression, coma and death; and falls and fractures in specific populations. The update includes labelling to reflect the risk of problematic use resulting in overdose or death, especially when used in combination with other medication, and includes information to address the risk of severe and life-threatening withdrawal symptoms after abrupt discontinuation of the drugs or rapid dose reduction. Impacted drugs include alprazolam, bromazepam, clobazam, clonazepam, diazepam, eszopiclone, flurazepam, lorazepam, midazolam, oxazepam, nitrazepam, temazepam, triazolam, zalepion, zolpidem, zopiclone, clorazepate dipotassium, chlordiazepoxide and chlordiazepoxide/clidinium bromide. Health Canada. Updates to safety labelling for benzodiazepines and benzodiazepine-like drugs. Internet Document : 30 Oct 2020. Available from: URL: https:/ /healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/74223a-eng.php
0114-9954/20/1830-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803515033
Reactions 14 Nov 2020 No. 1830
Data Loading...
